Abstract
Moyamoya disease (MMD) is an unusual vasculopathy in which the blood vessels of the brain are occluded, resulting in thrombosis. When MMD occurs in association with an underlying pathology, it is known as moyamoya syndrome. The association of moyamoya syndrome with sickle cell disease is uncommon. Herein, we report a case of moyamoya syndrome in a 32-year-old male adult patient.
Keywords: moyamoya disease, moyamoya syndrome, sickle cell disease, vasculopathy
Introduction
Moyamoya disease (MMD) is an uncommon progressive vasculopathy that affects the cerebral arteries. It is characterized by stenotic changes involving the brain blood vessels, most commonly the internal carotid artery (ICA). Characteristically, MMD is associated with a pathological formation of a new blood vessel known as ‘moyamoya vascular’, which is a Japanese term that denotes a cloud of smoke. This term was first introduced in 1969 to describe the radiological findings of these distinct blood vessels in cerebral angiograms [1-4].
Epidemiologically, MMD occurs mostly in children and rarely in adults [5]. Additionally, MMD has a high incidence rate in East Asian countries, predominantly Korea and Japan (three cases per 100,000 of the pediatric population). In Europe, the incidence rate of MMD is comparatively ten times lower [5]. In Saudi Arabia, the incidence rate of MMD is not well-defined; however, it is extremely rare with roughly less than 20 reported cases. They were mostly scattered case reports [6,7] and small-sized case series involving pediatric patients [8-11].
MMD refers to the disease itself without a predisposing condition. However, moyamoya syndrome (MMS) refers to MMD in the presence of a predisposing condition, such as neurofibromatosis, systemic lupus erythematosus, tuberous sclerosis and sickle cell disease (SCD) [1,12]. The association of SCD with MMS is uncommon [13]. To the best of our knowledge, less than 200 cases have been reported around the world [14]. Specifically, in Saudi Arabia, only three cases of MMS in association with SCD have been reported and all of them involved pediatric patients [8,9]. Herein, we report the first case of MMS in a sickler Saudi Arabian adult patient.
Case presentation
A 32-year-old Saudi Arabian male sickler patient presented to the emergency department with a six-hour history of sudden and continuous shortness of breath. The history was obtained from the mother. The patient’s current presentation was associated with agitation and a sudden change in behavior. The patient was shouting and refusing to communicate with doctors. The mother denied any history of orthopnea, cough or fever during the patient’s current presentation. Past medical history was remarkable for SCD since childhood with infrequent hospital visits. Socially, the patient was single, non-smoker and living with his family.
On general examination, the patient looked ill, anxious and sitting on the bed lying forward connected to an oxygen mask. The body mass index (BMI) was 18.5 kg/m2. Vital signs showed blood pressure: 125/80 mmHg, pulse: 110 beats/min, respiratory rate: 28 breaths/min, temperature: 39 degrees Celsius and oxygen saturation: 87% on room air and 94% on 5 liters of oxygen. Respiratory and cardiovascular examinations were normal. Hemoglobin electrophoresis showed a hemoglobin S (Hb S) level of 78%. Laboratory testing for D-dimer showed 12 ng/L (normal range is < 0.5 ng/L). Pulmonary embolism was suspected and chest spiral computed tomography (CT) scan showed bilateral consolidation without acute pulmonary embolism. In consideration of the fever and agitation, the patient received ceftriaxone, vancomycin and diazepam.
CT scan of the head without contrast showed left frontal subcortical deep white matter hypodensity, most likely representing chronic watershed infarction. Moreover, there was left frontal cortical gray matter hypodensity, most likely representing cerebral atrophy (Figure 1). There were no signs of acute hemorrhage or ischemic infarction. Magnetic resonance angiography (MRA) showed severely hypoplastic left ICA and abnormal tortuous collateral vessels around the circle of Willis (Figure 2). No arteriovenous malformation or aneurysm was noted.
Based on the clinical and radiological findings, the final differential diagnosis was suggestive of a progressive vascular occlusive process which could be seen in MMD. Hematology team was consulted for further evaluation. The patient received a blood transfusion three times daily for 16 days. The patient dramatically improved and returned to his regular behavior. The patient was discharged home on aspirin 81 mg daily. The patient was seen four weeks later at the neurology clinic and he was doing well.
Discussion
The exact pathogenesis of MMD is not clearly understood [13]. Risk factors for MMD include East Asian genetics, pediatric age group, female gender and family history of MMD [1,4,12]. Common underlying conditions associated with MMS include neurofibromatosis, systemic lupus erythematosus, tuberous sclerosis, periarteritis nodosa, mesial temporal sclerosis, thyrotoxicosis, Down’s syndrome and previous radiation therapy [1,4,12]. The association of MMS with SCD is not common [14]. MMD typically involves children in the first decade of life (average is nine years of age) and rarely adults (around 30-40 years of age) [5,15]. Children most often present to clinical attention with ischemic strokes or seizures. On the other hand, adults most commonly present to clinical attention with hemorrhagic strokes [4]. Epidemiological studies confirm that MMD/MMS is most frequent in East Asian countries and very occasional in Western countries [4]. Our patient was an adult of a Middle-eastern origin and presented with shortness of breath and agitation.
Diagnostic criteria for definitive MMD include occlusive changes at the ICA bilaterally or unilaterally as well as abnormal collateral blood vessels based on radiological imaging [4,5]. Catheter angiography is the definitive diagnostic test; however, it is relatively invasive. MRA and CT angiography are the best and practical diagnostic tests. This is because they are less invasive and can detect distal steno-occlusion in ICA and/or middle cerebral artery. Nonetheless, they are less sensitive to detect basal collaterals [4,5,16].
Medical management of MMS with SCD includes blood transfusions which can reduce the clinical symptoms and complications such as strokes, transient ischemic attacks and seizures. Nevertheless, recent studies imply chronic transfusions do not prevent the disease progression and that revascularization surgeries are actually more effective in the long-run, especially before the onset of neurological deficits [1,12,14,17,18].
The natural history of MMD is wide-ranging. Disease progression can occur slowly with occasional stroke-like events or rapidly with advanced neurologic decline [19]. Even among asymptomatic patients, the rate of disease progression over time is high without surgical management [20]. The neurologic status at the time of management is the most important factor that predicts long-term outcomes in patients with MMD [19]. Additionally, irrespective of treatment, once a major neurologic incident occurs, such as stroke or bleeding, the patient may experience a permanent loss of function with poor prognosis. Thus, early diagnosis of MMD along with prompt surgical intervention is central to achieving better disease outcomes.
Conclusions
In conclusion, MMD is an uncommon progressive vasculopathy that mostly affects cerebral arteries. Although rare, however, MMS should be considered in the differential diagnosis in adults with SCD and presenting with shortness of breath. Brain angiography can aid in establishing the definitive diagnosis. Revascularization surgery is preferred over medical treatment in patients with MMS and SCD.
The content published in Cureus is the result of clinical experience and/or research by independent individuals or organizations. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. All content published within Cureus is intended only for educational, research and reference purposes. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. Do not disregard or avoid professional medical advice due to content published within Cureus.
The authors have declared that no competing interests exist.
Human Ethics
Consent was obtained by all participants in this study
References
- 1.Cerebral vasculopathy in children with sickle cell anemia. Fasano RM, Meier ER, Hulbert ML. https://www.ncbi.nlm.nih.gov/pubmed/25294561. Blood Cells Mol Dis. 2015;54:17–25. doi: 10.1016/j.bcmd.2014.08.007. [DOI] [PubMed] [Google Scholar]
- 2.Moyamoya in children with sickle cell anemia and cerebrovascular occlusion. Seeler RA, Royal JE, Powe L, Goldberg HR. J Pediatr. 1978;93:808–810. doi: 10.1016/s0022-3476(78)81086-5. [DOI] [PubMed] [Google Scholar]
- 3.Diffuse cerebral oedema from sickle cell vaso-occlusive crisis. Weaver MD, Dayoub H, Damuth E, Kavi T. BMJ Case Rep. 2017;2017:0. doi: 10.1136/bcr-2017-221345. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Epidemiology, diagnosis and treatment of moyamoya disease. Zhang H, Zheng L, Feng L. Exp Ther Med. 2019;17:1977–1984. doi: 10.3892/etm.2019.7198. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Moyamoya disease: diagnostic imaging. Tarasów E, Kułakowska A, Lukasiewicz A, Kapica-Topczewska K, Korneluk-Sadzyńska A, Brzozowska J, Drozdowski W. https://www.ncbi.nlm.nih.gov/pubmed/22802820. Pol J Radiol. 2011;76:73–79. [PMC free article] [PubMed] [Google Scholar]
- 6.Fanconi anemia associated with moyamoya disease in Saudi Arabia. Al-Hawsawi ZM, Al-Zaid MA, Barnawi AI, Yassine SM. https://www.ncbi.nlm.nih.gov/pubmed/25719591. Saudi Med J. 2015;36:233–235. doi: 10.15537/smj.2015.2.9978. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Atypical location of intracerebral hemorrhage in moyamoya disease. Abuoliat ZA, AlFarhan BA, Alshahrani AA, AlFarhan AA, Almuntashri MA, Alotaibi N. Cureus. 2017;9:0. doi: 10.7759/cureus.1948. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Hematologic risk factors for stroke in Saudi children. Salih MA, Abdel-Gader AG, Al-Jarallah AA, et al. https://www.ncbi.nlm.nih.gov/pubmed/16532128. Saudi Med J. 2006;27:21–34. [PubMed] [Google Scholar]
- 9.Moyamoya syndrome as a risk factor for stroke in Saudi children. Novel and usual associations. Salih MA, Murshid WR, Al-Salman MM, et al. https://www.researchgate.net/publication/7246653_Moyamoya_syndrome_as_a_risk_factor_for_stroke_in_Saudi_children_Novel_and_usual_associations. Saudi Med J. 2006;27:69–80. [PubMed] [Google Scholar]
- 10.Stroke in Saudi children. Epidemiology, clinical features and risk factors. Salih MA, Abdel-Gader AG, Al-Jarallah AA, et al. https://www.researchgate.net/publication/7246646_Stroke_in_Saudi_children_-_Epidemiology_clinical_features_and_risk_factors. Saudi Med J. 2006;27:12–20. [PubMed] [Google Scholar]
- 11.Childhood stroke in Eastern Province, KSA: pattern, risk factors, diagnosis and outcome. Emam AT, Ali AM, Babikr MA. Acta Paediatr. 2009;98:1613–1619. doi: 10.1111/j.1651-2227.2009.01421.x. [DOI] [PubMed] [Google Scholar]
- 12.Moyamoya syndrome in sickle cell anaemia: a cause of recurrent stroke. Soares D, Bullock R, Ali S. BMJ Case Rep. 2014;2014:0. doi: 10.1136/bcr-2014-203727. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Anesthesia for cerebral revascularization for adult moyamoya syndrome associated with sickle cell disease. Chong CT, Manninen PH. J Clin Neurosci. 2011;18:1709–1712. doi: 10.1016/j.jocn.2011.03.026. [DOI] [PubMed] [Google Scholar]
- 14.Outcomes in patients with moyamoya syndrome and sickle cell disease: a systematic review. Newman S, Boulter JH, Malcolm JG, Pradilla I, Pradilla G. World Neurosurg. 2020;135:165–170. doi: 10.1016/j.wneu.2019.11.137. [DOI] [PubMed] [Google Scholar]
- 15.Childhood moyamoya: looking back to the future. Dlamini N, Muthusami P, Amlie-Lefond C. Pediatr Neurol. 2019;91:11–19. doi: 10.1016/j.pediatrneurol.2018.10.006. [DOI] [PubMed] [Google Scholar]
- 16.Case report: a case report of Moyamoya disease in a 36 year old African American woman. Gudepu RK, Qureshi MA, Qureshi IA, Rao L. F1000 Res. 2014;3:297. doi: 10.12688/f1000research.5859.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Clinical outcome after 450 revascularization procedures for moyamoya disease. Guzman R, Lee M, Achrol A, et al. J Neurosurg. 2009;111:927–935. doi: 10.3171/2009.4.JNS081649. [DOI] [PubMed] [Google Scholar]
- 18.Meta-analysis of prognosis of different treatments for symptomatic moyamoya disease. Li Q, Gao Y, Xin W, et al. World Neurosurg. 2019;127:354–361. doi: 10.1016/j.wneu.2019.04.062. [DOI] [PubMed] [Google Scholar]
- 19.Long-term outcome in children with moyamoya syndrome after cranial revascularization by pial synangiosis. Scott RM, Smith JL, Robertson RL, Madsen JR, Soriano SG, Rockoff MA. J Neurosurg. 2004;100:142–149. doi: 10.3171/ped.2004.100.2.0142. [DOI] [PubMed] [Google Scholar]
- 20.Incidence and clinical features of disease progression in adult moyamoya disease. Kuroda S, Ishikawa T, Houkin K, Nanba R, Hokari M, Iwasaki Y. Stroke. 2005;36:2148–2153. doi: 10.1161/01.STR.0000182256.32489.99. [DOI] [PubMed] [Google Scholar]